Treatment of Prurigo Nodularis
For adult patients with prurigo nodularis, initiate treatment with high-potency topical corticosteroids under occlusion combined with narrowband UVB (NB-UVB) phototherapy, while simultaneously addressing the itch-scratch cycle with gabapentinoids or antidepressants; for moderate-to-severe disease, dupilumab is the first FDA-approved biologic and should be strongly considered as first-line systemic therapy.
Initial Assessment and Diagnosis
Before initiating treatment, confirm the diagnosis requires three core elements present simultaneously:
- Pruritus lasting ≥6 weeks with intense, relentless quality
- History or visible signs of repeated scratching, picking, or rubbing
- Firm, hyperkeratotic nodular lesions on extensor surfaces 1
Evaluate for common comorbidities that may influence treatment selection: atopic dermatitis, diabetes, chronic kidney disease, liver disease, thyroid disorders, HIV, and mental health conditions (anxiety/depression) 2. These are not triggers but associated conditions that require parallel management.
Treatment Algorithm by Disease Severity
First-Line Topical Therapy (All Patients)
High-potency topical corticosteroids are recommended as initial therapy 3. The evidence shows significantly improved efficacy when used:
- Under occlusive dressing (enhances penetration and prevents scratching) 4
- In combination with other modalities rather than monotherapy 4
Alternative topical agents that are suggested include:
Avoid topical capsaicin and calamine lotion - these have not demonstrated benefit 5.
Phototherapy (Strongly Recommended)
Narrowband UVB (NB-UVB) phototherapy is recommended as a cornerstone treatment 3, 6. The evidence base is substantial:
- Effective for breaking the itch-scratch cycle
- Can be used as monotherapy or combined with topicals
- Onset of effect typically noticed from 2 weeks into treatment 5
Important caveat: High relapse rates occur after discontinuation (symptoms recurring 3-24 weeks later), so maintenance therapy may be needed 5.
Alternative phototherapy options that can be considered:
Systemic Therapy for Moderate-to-Severe Disease
Biologic Therapy (First-Line for Moderate-to-Severe)
Dupilumab (IL-4/IL-13 inhibitor) is recommended as the first and only FDA-approved biologic specifically for moderate-to-severe prurigo nodularis 3, 7. This represents the most significant therapeutic advance and should be prioritized for:
- Patients with widespread disease
- Those failing topical therapy and phototherapy
- Patients with significant quality of life impairment
Nemolizumab (IL-31 receptor antagonist) is also recommended as another approved biologic option 3, 8.
Conventional Systemic Agents (Second-Line)
When biologics are not accessible or appropriate, the following are suggested:
Gabapentinoids (gabapentin or pregabalin):
Antidepressants:
- Mirtazapine, paroxetine, or fluvoxamine 5, 3
- Address both pruritus and commonly comorbid depression/anxiety
- Patients prioritize rapid itch relief above all other outcomes 9
Immunosuppressants (suggested):
μ-opioid receptor antagonists (naltrexone) - suggested 3
JAK inhibitors - suggested as emerging option 3, 10
Agents to Avoid or Use with Caution
Do NOT use:
- Non-sedating antihistamines as monotherapy (cetirizine, fexofenadine) - not effective for prurigo nodularis 5
- Long-term sedating antihistamines (risk of dementia) except in palliative care 5
No recommendation can be made for azathioprine, retinoids, neurokinin-1 receptor antagonists, thalidomide, or lenalidomide due to insufficient evidence 3.
Lesion-Directed Interventions
For individual resistant nodules, the following are suggested:
- Intralesional corticosteroids (triamcinolone acetonide) 3, 4
- Cryotherapy - may help with adherence challenges and avoid systemic medication 3, 4
Treatment Prioritization Based on Patient Preferences
Critical insight: Patients with prurigo nodularis prioritize rapid onset of itch reduction (within days to weeks) over long-term skin healing, safety concerns, or administration frequency 9. The conditional relative importance of itch relief is 7.4 times greater than skin lesion improvement and nearly twice as important as achieving complete itch resolution at 16 weeks.
This means your treatment selection should emphasize:
- Fastest itch control: Gabapentinoids, antidepressants, or dupilumab
- Breaking the itch-scratch cycle immediately: High-potency topical corticosteroids under occlusion
- Sustained benefit: NB-UVB phototherapy + systemic therapy
Common Pitfalls to Avoid
Treating as generalized pruritus without rash: Prurigo nodularis is a distinct inflammatory disease requiring specific therapy, not just antipruritic management 2
Relying on antihistamines: These are ineffective as monotherapy and waste valuable treatment time 5
Stopping phototherapy too early: Maintenance therapy is often needed to prevent relapse 5
Ignoring comorbidities: Uncontrolled diabetes, kidney disease, or mental health conditions will undermine treatment success 2
Delaying biologic therapy: In moderate-to-severe disease, dupilumab should be considered early rather than cycling through multiple ineffective conventional agents 7
Monitoring and Adjustment
Assess treatment efficacy regularly using:
- Pruritus intensity scales (patient priority) 9
- Lesion counts and healing
- Quality of life measures
- Sleep quality (commonly impaired) 2
If inadequate response after 8-12 weeks of optimized topical therapy plus phototherapy, escalate to systemic therapy. For patients already on systemic therapy without adequate response, transition to biologic agents 8.